Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 9 of 9 publications.

Domenech E, Fortuny J, Martinez D, Tormos A, Huang Z, Hill D, Weinstein C, Esslinger S, Krumme A, Mines D, Gisbert J. A post-authorization safety study of golimumab in ulcerative colitis using the Spanish ENEIDA registry (MK8259-042). Poster presented at the 2024 ISPE Annual Meeting; August 28, 2024. Berlin, Germany.

Rebordosa C, Thomsen RW, Tave AK, Madsen M, Beachler DC, Martinez D, Garcia-Esteban R, Plana E, Tormos A, Farsani SF, Perez-Gutthann S, Pladevall-Vila M. Liver, renal, genitourinary, and diabetic ketoacidosis risks among new users of empagliflozin versus DPP-4 inhibitors in patients with type 2 diabetes: post-authorisation safety study based on multinational cohorts. Diabetes Obes Metab. 2024 Apr;26(4):1291-304. doi: 10.1111/dom.15429

Tormos A, Thomsen RW, Tave AK, Madsen M, Beachler DC, Martinez D, Garcia Esteban R, Plana E, Farsani SF, Perez-Gutthann S, Pladevall-Vila M, Rebordosa C. Post-authorisation safety study (PASS) assessing the risk of liver, renal, genitourinary, and diabetic ketoacidosis outcomes among users of empagliflozin versus DPP-4 inhibitors in patients with type 2 diabetes mellitus (T2D). Poster presented at the 39th ICPE Annual Conference; August 27, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):585. doi: 10.1002/pds.5687

Jacquot E, Collin E, Ladner A, Tormos A, Hamm L, Perez-Gutthann S, Gutierrez L, Chirila C, Deltour N. Agomelatine drug utilisation study in selected European countries: a multinational, observational study to assess effectiveness of risk-minimisation measures. Pharmaceut Med. 2019 Aug;33(4):311-9. doi: 10.1007/s40290-019-00291-2

Tormos A, Rebordosa C, Thomas S, Plana E, Rasouliyan L, Pladevall-Vila M, Fazeli-Farsani S, Deruaz-Luyet A, Brodovicz KG, Perez-Gutthann S. Time between laboratory tests and acute liver and kidney injury diagnosis codes in CPRD: are we doing it right? Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):452. doi: 10.1002/pds.4629

Fortuny J, Rasouliyan L, Mines D, Tormos A, Earley E, Perez-Gutthann S, Domenech E, Gisbert JP. Characterization of patients with ulcerative colitis in a post-authorization safety study of golimumab based in the Spanish ENEIDA Registry. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 24, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):47. doi: 10.1002/pds.4629

Puig-Barbera J, Tormos A, Trushakova S, Sominina A, Pisareva M, Ciblak MA, Badur S, Yu H, Cowling BJ, Burtseva E, GIHSN Group. The Global Influenza Hospital Surveillance Network (GIHSN): a new platform to describe the epidemiology of severe influenza. Influenza Other Respi Viruses. 2015 Jul 21. doi: 10.1111/irv.12335

Puig-Barbera J, Natividad-Sancho A, Launay O, Burtseva E, Ciblak MA, Tormos A, Buiques-Vila A, Martinez-Ubeda S, Sominina A, GIHSN Group. 2012-2013 Seasonal influenza vaccine effectiveness against influenza hospitalizations: results from the global influenza hospital surveillance network. PLoS One. 2014 Jun 19;9(6):e100497.

Puig-Barbera J, Tormos A, Sominina A, Burtseva E, Launay O, Ciblak MA, Navtividad-Sancho A, Buigues-Vila A, Martinez-Ubeda S, Mahe C, GIHSN Group. First-year results of the Global Influenza Hospital Surveillance Network: 2012-2013 Northern hemisphere influenza season. BMC Public Health. 2014 Jun 5;14:564. doi: 10.1186/1471-2458-14-564.